MEXIPRIM (Emoxypine succinate)

Instructions for MEXIPRIM (Emoxypine succinate)

Prepart Components

Intravenous and intramuscular solution 1 ml
active substance:
ethylmethylhydroxypyridine succinate 50 mg
auxiliary substances: water for injection - up to 1 ml

Coated tablets 1 table.
active substance MEXIPRIM:
ethylmethylhydroxypyridine succinate (100% substance) 125 mg
auxiliary substances (core): kaolin; sodium carboxymethyl starch; ICC; C17 povidon; talc; calcium stearate
film sheath: hypromellose; macrogol; titanium dioxide; talc

Description of the drug MEXIPRIM form

Solution for intravenous and intramuscular injection. Colorless or slightly yellowish transparent liquid.

Pills covered with film sheath. Round double-convex tablets covered with a film shell in white or almost white. The cross section is white to white with a grayish or yellowish or brownish hue.
MEXIPRIM Solution for intravenous and intramuscular injection, 50 mg/ml.

For 5 ampoules in PVC film or PVC film and flexible packaging based on aluminum foil, or PVC film and aluminium printed foil laminated.
For 1 or 2 contoured pockets, together with instructions for use, a knife or a scarifier, are placed in a pack of cardboard.
For stationary 6, 12, 20, 50 or 100 contoured foil-packed boxes with 6, 12, 20, 50 or 100, together with instructions for use, knives or scarifiers, ampoules are placed in cardboard boxes or corrugated cardboard boxes.

Pharmacological effect MEXIPRIM:

Pharmacological effects are anxiolytic, antioxidant.

Pharmacodynamics MEXIPRIM:

An antioxidant preparation derived from 3-oxypyridine; it has antihypoxic, membrane-protective, nootropic, anticonvulsive, stress-protective, anxiolytic effects. The preparation increases the body's resistance to the effects of major damaging factors, oxygen-dependent pathological conditions (shock, hypoxia and ischemia, disruption of cerebral circulation, intoxication by alcohol and antipsychotic preparations (neuroleptics).

The mechanism of action of ethylmethylhydroxypyridine succinate is caused by antioxidant, antihypoxant and membrane protective action. The preparation reduces manifestations of oxidative stress, inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio and improves the structure and function of the cell membrane. The preparation modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, promotes the preservation of the structural-functional organization of biomembranes, the transport of neurotransmitters and improves synaptic transmission. The drug MEXIPRIM increases the dopamine content in the brain. The invention makes it possible to increase the compensatory activation of aerobic glycolysis and to reduce the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia conditions, to increase the ATP and creatinphosphate content, to activate the mitochondrial energy-synthesizing functions and to stabilise cell membranes.

Egilmethylhydroxypyridine succinate normalizes metabolic processes in the ischemized myocardium and improves its functional state, reduces the necrosis zone, restores and improves the electrical activity and contractility of myocardium, as well as increases coronary blood flow in the ischemia zone, reduces the effects of reperfusion syndrome in acute coronary insufficiency. In the conditions of coronary insufficiency it increases collateral blood supply of ischemized myocardium, promotes preservation of cardiomyocyte integrity and maintenance of their functional activity. Effectively restores myocardial contractility in case of reversible heart dysfunction. Increases antianginal activity of nitrodrugs.
Improves metabolism and blood supply of brain tissues, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (red blood cells and platelets). It has a hypolipidemic effect, reduces the total Hs and LDL content.
It promotes the preservation of retinal ganglion cells and optic nerve fibers in the case of progressive neuropathy caused by chronic ischemia and hypoxia. It improves the functional activity of the retina and optic nerve, increasing visual acuity.
The drug MEXIPRIM reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
It exhibits an anxiolytic effect which is not accompanied by a muscle relaxant effect, exhibits nootropic properties, prevents and reduces learning and memory disturbances arising from aging and the action of various pathogenic factors, has an anticonvulsive effect, and increases attention concentration and efficiency.
Antistress action is manifested in normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various brain structures.

Indications for use MEXIPRIM:

Solution for intravenous and intramuscular injection.
disorders of cerebral circulation
Brain injury, traumatic brain injury.
Discirculatory encephalopathy.
Vegetative dystonia syndrome.
Mild cognitive disorders of atherosclerotic genesis.
Anxiety disorders in neurotic and neurotic conditions.
Acute myocardial infarction (from the first day as part of complex therapy).
Primary open-angle glaucoma of various stages, as part of complex therapy.
The treatment of withdrawal syndrome in alcoholism with the predominance of neurotic and vegetative vascular disorders.
Acute intoxication by antipsychotic agents.
Acute pyo-inflammatory processes of the abdomen (acute necrotizing pancreatitis, peritonitis), as part of complex therapy.
Pills MEXIPRIM covered with film sheath.
The effects of acute brain circulation disorders, in pm after transient ischemic attacks, in the subcompensation phase as preventive courses.
Mild traumatic brain injury, consequences of brain injuries.
Encephalopathy of different genesis (discirculatory, dismetabolic, post-traumatic, mixed).
Vegetative dystonia syndrome.
Mild cognitive disorders of atherosclerotic genesis.
Anxiety disorders in neurotic and neurotic conditions.
Ischemic heart disease in complex therapy.
The treatment of withdrawal syndrome in alcoholism with the predominance of neurotic and vegetative-vascular disorders, post-abstinent disorders.

Conditions after acute intoxication by antipsychotic agents.
Asthenic conditions, as well as prevention of the development of somatic diseases under the influence of extreme factors and loads.

Contraindications MEXIPRIM:

Increased sensitivity to the active substance and other components of the drug MEXIPRIM.
Acute liver and kidney dysfunction.
Pregnancy, breastfeeding, childhood - due to the lack of knowledge of the drug MEXIPRIM.
Use in pregnancy and breastfeeding
The use of Mexprim in pregnancy and during breastfeeding is contraindicated due to the lack of data on the effectiveness and safety of the use of the drug MEXIPRIM during these periods.

Side effects MEXIPRIM:

In order to avoid side effects, it is recommended to follow the dosing regime and the rate of administration of the drug. The incidence of side effects was determined according to the WHO classification: very often (≥10%); often (≥1, < 10%); infrequently (≥0.1.
From the immune system. Very rarely - anaphylactic shock, angioedema, urticaria.
On the psychic side. Very rarely - drowsiness.
From MEXIPRIM the nervous system. Very rarely - headache, dizziness (may be due to excessive speed of injection and is short-term).
From the side of the vessels. Very rarely - lowering of AD, increasing of AD (may be associated with excessively high rate of introduction and is short-term).
From the respiratory system, chest organs and mediastinum. Very rarely - dry cough, throat, chest discomfort, shortness of breath (may be due to excessive speed of introduction and is short-term).
From the Housing Department. Very rarely - dry mouth, nausea, a feeling of unpleasant smell, a metallic taste in the mouth.
From the skin and subcutaneous tissue. Very rarely - itching, rash, hyperemia.
General disturbances and reactions at the injection site. Very rarely - a feeling of warmth.

Method of use and doses MEXIPRIM:

Solution for intravenous and intramuscular injection.
B/m, B/W (jet or drip). The infusion method of administration requires diluting the preparation in a 0.9% sodium chloride solution. The jet stream is slowly administered for 5-7 minutes, drip-fed at a rate of 40-60 drops per minute.
Dosing mode is selected individually.

Acute disorders of cerebral circulation (as part of complex therapy). In the first 10-14 days B/V drip for 200-500 mg 2-4 times per day, then - B/M for 200-250 mg 2-3 times per day for 2 weeks.
MEXIPRIM Brain injury, traumatic brain injury: For 10-15 days B/B drip 200-500 mg 2-4 times a day.
Discirculatory encephalopathy in the discompensation phase. B/B fluted or drip in a dose of 200-500 mg 1-2 times per day for 14 days, then - B/M for 100-250 mg/day for the next 2 weeks.
Course prophylaxis of dicirculatory encephalopathy. B/m in a dose of 200-250 mg twice daily for 10-14 days.
Vegetative dystonia syndrome, neurotic and neurotic states. B/m 50-400 mg/day for 14 days.
Mild cognitive impairment of atherosclerotic genesis (in elderly patients), anxiety disorders: b/m in a dose of 100-300 mg/day for 14-30 days.
Acute myocardial infarction (from the first day as part of complex therapy). B/V or B/M for 14 days, the drug MEXIPRIM is used against the background of the standard treatment of myocardial infarction, which includes nitrates, beta-adrenolocators, ACE inhibitors, thrombolics, anticoagulants and antiaggregants, as well as symptomatic agents according to indications.
In the first 5 days, in order to achieve the maximum effect, the preparation is injected into/into, and in the subsequent 9 days the preparation can be administered into/out.
B/V is produced by drip infusion, slowly (to avoid side effects) for 30-90 min (in 100-150 ml 0.9% sodium chloride solution or 5% dextrose (glucose) solution MEXIPRIM. Slow if necessary

Inside. For 125-250 mg (1-2 table) 3 times per day.
The initial dose is 125-250 mg (1-2 table) 1-2 times a day with gradual increase until a therapeutic effect is achieved. The maximum daily dose is 750 mg (Table 6).
The duration of treatment is 2-6 weeks, for the purchase of alcohol withdrawal - 5-7 days. The duration of the course of therapy in patients with IBS is not less than 1.5-2 months. Treatment is discontinued gradually, reducing the dose within 2-3 days.
Repeat courses (on the recommendation of the doctor) should preferably be held in the spring and autumn periods

Special Instructions:

The effect of ethylmethylhydroxypyridine succinate increases the action of tranquilizing, anticonvulsant drugs, which may require adjustment of the dose of the respective drugs MEXIPRIM.
The drug is not prescribed to children under 18 years of age due to insufficient knowledge of the action of the drug MEXIPRIM.
Influence on the ability to drive vehicles, machinery. During treatment, care must be taken when driving and engaging in other potentially hazardous activities requiring increased focus and rapid psychomotor responses.